The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Xatral 10mg Prolonged Release Tablets

10mg milligram(s) Tablet

Sanofi-Aventis Ireland Limited T/A SANOFIPA0540/162/003

Main Information

Trade NameXatral 10mg Prolonged Release Tablets
Active SubstancesALFUZOSIN HYDROCHLORIDE
Strength10mg milligram(s)
Dosage FormTablet
Licence HolderSanofi-Aventis Ireland Limited T/A SANOFI
Licence NumberPA0540/162/003

Group Information

ATC CodeG04CA Alpha-adrenoreceptor antagonists
G04CA01 alfuzosin

Status

Authorised/WithdrawnAuthorised
Licence Issued26/05/2000
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceNone
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back